The role of intravitreal trimethoprim/sulfamethoxazole in the treatment of toxoplasma retinochoroiditis
Copyright 2015, SLACK Incorporated.
| Veröffentlicht in: | Ophthalmic surgery, lasers & imaging retina. - 2013. - 46(2015), 1 vom: 15. Jan., Seite 137-40 |
|---|---|
| 1. Verfasser: | |
| Weitere Verfasser: | , , , , |
| Format: | Online-Aufsatz |
| Sprache: | English |
| Veröffentlicht: |
2015
|
| Zugriff auf das übergeordnete Werk: | Ophthalmic surgery, lasers & imaging retina |
| Schlagworte: | Case Reports Journal Article Anti-Infective Agents Antibodies, Protozoan Immunoglobulin G Dexamethasone 7S5I7G3JQL Trimethoprim, Sulfamethoxazole Drug Combination 8064-90-2 |
| Zusammenfassung: | Copyright 2015, SLACK Incorporated. The authors evaluate the role of intravitreal trimethoprim/sulfamethoxazole in the treatment of toxoplasma retinochoroiditis (TRC) in four patients. Intravitreal injection of trimethoprim/sulfamethoxazole 1.28 mg/0.08 mL with dexamethasone 400 µg/0.1 mL was injected weekly or biweekly. After the initiation of treatment, a reduction in intraocular inflammation was observed clinically and on optical coherence tomography within 1 week. Three patients regained visual acuity of 20/20, and one patient improved to 20/40 with residual macular scarring. No evidence of retinal toxicity was noted on full-field electroretinogram. Intravitreal trimethoprim/sulfamethoxazole and dexamethasone combination may be an alternative treatment strategy in patients with TRC |
|---|---|
| Beschreibung: | Date Completed 18.06.2015 Date Revised 31.03.2022 published: Print Citation Status MEDLINE |
| ISSN: | 2325-8179 |
| DOI: | 10.3928/23258160-20150101-27 |